&NA;Gavestinel (GV 150526A, GV 150526), an indole derivative, is a glycine-site NMDA receptor antagonist that is in worldwide phase III trials with Glaxo Wellcome for the treatment of ischaemic and haemorrhagic stroke. The target number of patients for these trials is 3000.Gavestinel is a potent and selective antagonist at the glycine site of the NMDA receptor. It has an excellent neuroprotective profile in animal models of stroke, with a wide therapeutic window. As such, gavestinel has the potential to be an important compound in the treatment of stroke.